Product image of Jazeta (Sitagliptin Hydrochloride) supplied by GNH India

Jazeta

Active Ingredient:
Sitagliptin Hydrochloride
Origin:
EU

Jazeta (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, acting as part of a comprehensive diabetes management plan.

GNH India supplies Jazeta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin Hydrochloride is used to manage hyperglycaemia in the type 2 diabetes mellitus pathway.

  • Type 2 diabetes mellitus (monotherapy): lowers HbA1c when added to diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to enhance glycaemic control.
  • Type 2 diabetes mellitus with renal impairment (dose‑adjusted): provides glycaemic control when dosing is adjusted for renal function.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in improved post‑prandial and fasting blood glucose levels.

Side Effects

Adverse reactions may occur with sitagliptin therapy.

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract inflammation.
  • Headache: transient mild to moderate pain.
  • Upper respiratory infection: symptoms of cough and congestion.
  • Gastrointestinal upset: nausea, abdominal discomfort.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: angioedema, urticaria, or anaphylaxis.
  • Joint pain: unexplained arthralgia.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Hepatic injury: elevated liver enzymes or hepatitis.

Precautions & Warnings

Before initiating sitagliptin, consider the following safety measures.

  • Renal function assessment: adjust dose in patients with impaired renal function.
  • Monitor for pancreatitis: discontinue if severe abdominal pain develops.
  • Assess for hypersensitivity: stop therapy if rash, angioedema, or other allergic signs appear.
  • Use with caution in the elderly: increased susceptibility to adverse events.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with other medicines; review the following categories.

Major Interactions (Avoid)

  • Concomitant insulin secretagogues: increased risk of hypoglycaemia.
  • Sulfonylureas: may potentiate hypoglycaemic episodes.
  • Duplicate DPP‑4 inhibition: avoid using another DPP‑4 inhibitor concurrently.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor renal function and electrolytes.
  • ACE inhibitors: watch for additive hypotensive effects.
  • Rifampin: may reduce sitagliptin plasma concentrations, requiring efficacy assessment.

Frequently Asked Questions

Jazeta contains sitagliptin hydrochloride, a DPP‑4 inhibitor indicated to improve glycaemic control in adults with type 2 diabetes mellitus when used as part of a diet and exercise regimen, either alone or in combination with other antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, helping to lower blood glucose levels.

The prescribed dose of Jazeta is determined by the treating healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Jazeta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas or insulin, sitagliptin offers glucose‑dependent insulin secretion, which reduces the risk of hypoglycaemia. Unlike metformin, it does not affect gastrointestinal absorption. It is often chosen when patients need additional glycaemic control without significant weight gain or hypoglycaemia.

Jazeta should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and potency throughout its shelf life.

Jazeta is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include pancreatitis, severe allergic reactions such as angioedema, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unusual skin lesions.

Jazeta is contraindicated in patients with a known hypersensitivity to sitagliptin or any of its excipients. It should also be avoided in individuals with a history of pancreatitis until the cause is clarified, and in patients where the prescriber determines the risks outweigh the benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT